The antibody was generated by Medarex’s UltiMAb Human Antibody Development System. Medarex may receive future milestone payments and royalties should this product candidate progress to commercialization and achieve
Under Dr Celniker’s leadership, Taligen intends to build its late-stage R&D operations in Cambridge while maintaining in Denver its early discovery activities that are closely aligned with an
Under the terms of the amendment, Avigen has agreed to pay up to $5 million in development-based milestone payments for the development of a proprietary, purer form of
The oral capsule containing ebselen, SPI-3005, will be tested in advanced stage lung cancer and head and neck cancer patients receiving platinum based chemotherapy. This marks the second
This novel research program may offer a new therapeutic solution using fullerene compounds for treating allergies and other conditions that play a central role in inflammatory reactions, such
The licensing collaboration between GlaxoSmithKline (GSK) and Aspen, and its joint venture partner, Strides Arcolab, signals a significant new strategy from GSK to accelerate sales growth in emerging
This anterior cervical plate system was designed to optimize anterior cervical fusion procedures while addressing the clinical needs of anterior cervical discectomy and fusion surgery. Pioneer Surgical’s SlimFuse
OPT-80, also known as PAR-101, is said to be a first in-class narrow spectrum antimicrobial agent with excellent activity against many clostridia, including Clostridium difficile, and moderate activity
The Onglyza (saxagliptin), a dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor, is an investigational drug under joint development by Bristol-Myers Squibb and AstraZeneca for the treatment of type 2 diabetes.
The agreement gives Palomar exclusive distribution rights to sell Beau Visage, a clinically proven skin imaging and consultation system, to medical professionals. Palomar’s customers can use Beau Visage
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.